Oral cavity complications in oncological and hemato-oncological patients
Authors:
S. Vokurka 1; P. Holečková 2; D. Navrátilová-Hrabánková 3; K. Jirsová 4; J. Liška 5; M. Novosadová 6; V. Jánská 7; E. Faber 8; S. Šípová 1; J. Cvek 9; L. Pochop 10; Š. Kozáková 11; P. Kouřilová 12; M. Labudíková 8
Authors place of work:
Onkologická a radioterapeutická klinika LF UK a FN Plzeň
1; Ústav radiační onkologie, Nemocnice Na Bulovce, Praha
2; I. interní klinika – klinika hematologie VFN v Praze
3; Integrované onkologické centrum, Nemocnice Na Pleši
4; Oddělení parodontologie, Stomatologická klinika, FN Plzeň
5; Nemocniční lékárna, FN v Hradci Králové
6; Lékárna FN Plzeň
7; Hemato-onkologická klinika FN Olomouc
8; Klinika onkologická LF OU a FN Ostrava
9; Klinika komplexní onkologické péče MOÚ Brno
10; Nemocniční lékárna, FN Brno
11; Interní hematologická a onkologická klinika FN Brno
12
Published in the journal:
Klin Onkol 2021; 34(2): 153-162
Category:
Short Communication
doi:
https://doi.org/10.48095/ccko2021153
Summary
Background: Oral cavity injuries are very significant complications in the treatment of oncological and hemato-oncological patients. Preventive and curative interventions and patient education reduce the risk of complications and their consequences. A working group of authors from professional groups prepared recommendations for care. Purpose: A basic summary of recommended interventions to prevent and treat oral cavity injuries in daily practice, defined on the basis of expert societies guidelines, trials, literature data and proven practice and on the consensus opinions of the authors group members. Results: Preventive measures and patient education are essential in the approach to dealing with oral injuries in chemotherapy, radiotherapy, risky targeted treatment and osteonecrosis of the jaw. Local care products are an important element of care, in case of infections, their antimicrobial action is essential, in case of graft-versus-host disease or in connection with targeted oncological therapy, corticoids are used. Conclusion: The recommended procedures contribute to the reduction of the development, severity and consequences of oral complications in oncological and hemato-oncological patients.
Keywords:
oral cavity – Chemotherapy – radiotherapy – mucositis – osteonecrosis of jaw – graft-versus-host disease – infection – nursing
Recommendations for care from the cooperation of the Supportive Care Group of Czech Society for Oncology, Czech Society for Hematology, Oncology Section of the Czech Nurses Association and Society for Radiation Oncology, Biology and Physics
Zdroje
1. Peterson DE, Boers-Doets CB, Bensadoun RJ et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2015; 26 (Suppl 5): 139–151. doi: 10.1093/annonc/mdv202
2. Lalla RV, Bowen J, Barasch A et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120 (10): 1453–1461. doi: 10.1002/cncr.28592
3. Ariyawardana A, Cheng KK, Kandwal A et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2019; 27 (10): 3985–3995. doi: 10.1007/s00520-019-04888-w.
4. Elad S, Raber-Durlacher J, Brennan MT et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the multinational association of supportive care in cancer / international society of oral oncology (MASCC/ISOO) and the European group for blood and marrow transplantation (EBMT). Support Care Cancer 2015; 23 (1): 223–236. doi: 10.1007/s00520-014-2378-x.
5. Vokurka S, Quinn B, Margulies A. The European Oral Care in Cancer Group (EOCC) – Evropská skupina pro péči o dutinu ústní pacientů s malignitami. [abstrakt]. Klin Onkol 2017; 30 (Suppl 1): VIII/324, 54.
6. European Oral Care in Cancer Group Guidance and Support. [online]. Available from: http: //www.eocc.co.uk/guidance/.
7. Coleman R, Body JJ, Aapro M et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014; 25 (Suppl 3): iii124–iii137. doi: 10.1093/annonc/mdu103.
8. Modr Z, Morávek J. Metoda chráněného koagula – zaklad racionální chemoprofylaxe v chirurgii. Časopis lékařů českých 1985; 124 (32): 1007–1010.
9. Bermúdez-Bejarano EB, Serrera-Figallo MA, Gutiérrez-Corrales A et al. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. J Clin Exp Dent 2017; 9 (1): e141–e149. doi: 10.4317/jced.53372.
10. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO offset publication no. 48, 1979.
11. Vokurka S. Mukozitida dutiny ústní a gastrointestinálního traktu u pacientů po chemoterapii – aktuální přehled. Klin Onkol 2007; 20 (1): 23–28.
12. National Cancer Institute common terminology criteria for adverse events (CTCAE) v5.0. [online]. Available from: https: //ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
13. Vokurka S, Hrušák D, Hrabě V et al. Základní klinické, stomatologické, otorinolaryngologické, zobrazovací vyšetření a odběr vzorků tkání. In: Samuel Vokurka et al. Postižení dutiny ústní onkologických pacientů. Praha: CurrentMedia, 2014.
14. Quinn B. Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. Eur J Cancer Care 2013; 22 (5): 564–579. doi: 10.1111/ecc.12073.
15. Treister N, Nieder M, Baggott C et al. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer 2017; 116 (1): 21–27. doi: 10.1038/bjc.2016.
16. Wong KH, Kuciejewska A, Sharabiani MT et al. A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol 2017; 122 (2): 207–211. doi: 10.1016/j.radonc.2016.06.015.
17. Jansma A, Vissink FK, Spijkervet JL et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 1992; 70: 2171–2180.
18. Madeswaran S, Jayachandran S. Sodium bicarbonate: a review and its uses in dentistry. Indian J Dent Res 2018; 29: 672–677.
19. Thomas ED, Blume KG, Forman SJ et al. Hematopoietic cell transplantation, 3rd ed. Malden, USA: Blackwell Publishing, 2004.
20. So-Eun CH, Hee-Seung K. Sodium bicarbonate solution versus chlorhexidine mouthwash in oral care of acute leukemia patients undergoing induction chemotherapy: a randomized controlled trial. Asian Nurs Res 2012; 6 (2): 60–66. doi: 10.1016/j.anr.2012.05.004.
21. Sklenář Z, Ščigel V (eds.). Magistraliter receptura ve stomatologii – 2. korigované vyd. Praha: Havlíček Brain Team, 2013.
22. Coskunses FM. Sodium bicarbonate mouth rinse: an uncommon complication. JCR 2012; 2: 4–5. doi: http: //dx.doi.org/10.17659/01.2012.0002.
23. DeWalt EM, Haines AK. The effects of specified stressors on healthy oral mucosa. Nurs res 1969; 18: 22–27.
24. Vokurka S, Bystřická E, Ščudlová J et al. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-L-PAM 200 mg/m2 autologous hematopoietic stem cell transplantation. Eur J Oncol Nurs 2011; 15 (5): 508–512. doi: 10.1016/j.ejon.2011.01.006.
25. Rugo HS, Seneviratne L, Beck JT et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 2017; 18: 654–662. doi: 10.1016/S1470-2045 (17) 30109-2.
26. Šípová S, Vrabcová L, Živná V et al. Obecné a specifické možnosti péče o sliznice dutiny ústní pacientů při chemoterapii, radioterapii a cílené terapii. [abstrakt]. Klin Onkol; 32 (Supl 1), XII/294, 65.
27. Vokurka S, Skardova J, Hruskova R et al. The effect of polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair) on oral microbial colonization and pain control compared with other rinsing solutions in patients with oral mucositis after allogeneic stem cells transplantation. Med Sci Monit 2011; 17 (10): CR572–CR576. doi: 10.12659/msm.881983.
28. Hašek J. Nové léčivé látky v magistraliter receptuře XIV – mikonazol a mikonazol-nitrát. Prakt lékáren 2013; 9 (4–5): 192–195.
29. Státní ústav pro kontrolu léčiv Česká republika a Evropské léková agentura EMA. Souhrn údajů o přípravku, SPORANOX 10 mg/ml perorální roztok. [online]. Dostupné z: http: //www.sukl.cz/modules/medication/detail.php?kod=0056067&tab=texts.
30. Vokurka S, Kozáková Š, Jánská V et al. Stomatitidy při terapii s inhibitory mTOR a další cílené onkologické terapii, možnosti ovlivnění a význam lokální kortikoterapie. Klin Onkol 2020; 33 (6): 436–439. doi: 10.48095/ccko2020436.
31. Ambrogio R, Levine M. Tranexamic acid as a hemostatic adjunct in dentistry. [online]. Available from: https: //www.aegisdentalnetwork.com/cced/2018/06/tranexamic-acid-as-a-hemostatic-adjunct-in-dentistry.
32. Huscher A, De Stefani A, Smussi I et al. Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer. J Palliat Med 2010; 13 (4): 357–358. doi: 10.1089/jpm.2009.0356.
34. Vokurka S, Skardova J, Karas M et al. Oropharyngeal mucositis pain treatment with transdermal buprenorphine in patients after allogeneic stem cell transplantation. J Pain Symptom Manage 2010; 39 (6): e4–e6. doi: 10.1016/j.jpainsymman.2010.02.003.
35. Modrá kniha České onkologické společnosti. Farmakoterapie nádorové bolesti. [online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/26-32-farmakoterapie-nadorove-bolesti/.
36. Technologický předpis pro magistraliter přípravu používaný v Nemocniční lékárně FN Hradec Králové.
37. Technologický předpis pro magistraliter přípravu používaný v Nemocniční lékárně FN Plzeň.
38. Technologický předpis pro magistraliter přípravu používaný v Nemocniční lékárně FN Brno a Masarykův onkologický ústav Brno.
39. Technologický předpis pro magistraliter přípravu používaný v Nemocniční lékárně FN Olomouc.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2021 Číslo 2
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- IgG4-releated disease
- Oral cavity complications in oncological and hemato-oncological patients
- FDG-PET/ CT for initial staging and response assessment in Castleman disease – retrospective single-center study of 29 cases
- The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma – review